Stereotactic Body Radiotherapy Combined With Lenvatinib With or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma

伦瓦提尼 医学 肝细胞癌 内科学 肿瘤科 放射治疗 索拉非尼
作者
Quan Wang,Xiaoquan Ji,Jing Sun,Aimin Zhang,Jun Jia,Teng Zhang,Wengang Li,Xuezhang Duan
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier]
被引量:1
标识
DOI:10.1016/j.ijrobp.2024.03.035
摘要

PurposeThe aim of this study was to compare the clinical benefit and safety of the triple combination of stereotactic body radiotherapy (SBRT), lenvatinib, and programmed cell death protein 1 (PD-1) inhibitors with the dual combination of SBRT and lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC).Methods and MaterialsPatients with uHCC who received SBRT in combination with lenvatinib and PD-1 inhibitors or SBRT in combination with lenvatinib alone as first-line treatment from October 2018 to July 2022 were reviewed in this study. The primary endpoints were overall survival (OS) and progression-free survival (PFS). The secondary endpoints were intrahepatic PFS, extrahepatic PFS, and objective remission rate. In addition, safety profiles were assessed by analyzing treatment-related adverse events between the two groups to assess safety profiles.ResultsIn total, 214 patients with uHCC who received combination therapy were included in this retrospective study. Among them, 146 patients received triple combination therapy of SBRT, lenvatinib, and PD-1 inhibitors (SBRT-L-P group), and 68 patients received dual therapy of SBRT and lenvatinib (SBRT-L group). The median OS times of the 2 groups were 31.2 months and 17.4 months, respectively (P < .001). The median PFS time was significantly longer in the SBRT-L-P group than in the SBRT-L group (15.6 months vs 8.8 months, P < .001). Additionally, the median intrahepatic PFS (17.5 vs 9.9 months, P < .001) and extrahepatic PFS (20.9 vs 11.6 months, P < .001) were significantly longer in the SBRT-L-P group than in the SBRT-L group. The objective remission rate in the SBRT-L-P group was higher than in the SBRT-L group (63.0 vs 39.7%, P = .002). The incidence and severity of treatment-related adverse events in the SBRT-L-P group were comparable to those in the SBRT-L group.ConclusionThe use of both lenvatinib and PD-1 inhibitors with SBRT in patients with uHCC was associated with improved overall survival compared with lenvatinib and SBRT alone with a manageable safety profile.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
kaerxifa发布了新的文献求助10
1秒前
1秒前
Someone应助ff采纳,获得10
3秒前
风趣问儿完成签到,获得积分10
4秒前
打打应助可爱慕卉采纳,获得10
5秒前
顺心裙子发布了新的文献求助10
6秒前
漠之梦完成签到,获得积分10
6秒前
wjs0406发布了新的文献求助10
6秒前
坦率黑米发布了新的文献求助10
7秒前
Amo完成签到,获得积分10
8秒前
斯文败类应助哈哈哈哈采纳,获得10
8秒前
8秒前
cm发布了新的文献求助10
11秒前
OKC完成签到,获得积分10
12秒前
12秒前
kaerxifa完成签到,获得积分10
12秒前
13秒前
深情安青应助bly采纳,获得10
14秒前
Ava应助原野小年采纳,获得10
15秒前
wjs0406完成签到,获得积分10
16秒前
白昼の月完成签到 ,获得积分0
17秒前
哈哈哈哈完成签到,获得积分20
17秒前
可爱慕卉完成签到,获得积分20
17秒前
赘婿应助莫西莫西采纳,获得10
18秒前
含蓄的明雪应助小太阳采纳,获得10
18秒前
JamesPei应助ncjdoi采纳,获得10
18秒前
和平星发布了新的文献求助10
18秒前
20秒前
倒背如流圆周率完成签到,获得积分10
20秒前
Andorchid完成签到,获得积分10
20秒前
烟花应助毕双洲采纳,获得10
21秒前
22秒前
bkagyin应助和平星采纳,获得10
22秒前
24秒前
25秒前
25秒前
原野小年发布了新的文献求助10
26秒前
26秒前
jzh关闭了jzh文献求助
27秒前
bly发布了新的文献求助10
28秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3155891
求助须知:如何正确求助?哪些是违规求助? 2807086
关于积分的说明 7871889
捐赠科研通 2465477
什么是DOI,文献DOI怎么找? 1312260
科研通“疑难数据库(出版商)”最低求助积分说明 629958
版权声明 601905